Trial Eligibility
Have you or someone you know been diagnosed with obstructive HCM?
CEDAR-HCM
CEDAR-HCM is currently recruiting pediatric participants to evaluate the safety and efficacy of an investigational drug for Obstructive Hypertrophic Cardiomyopathy.
CEDAR-HCM is a phase 2/3 placebo-controlled clinical trial researching the investigational drug called aficamten.
Who
Children and adolescents diagnosed with obstructive HCM and are experiencing symptoms of HCM.
Where
Site locations are within the United States; this website is limited to providing information related to sites in this country. For more information, please visit https://clinicaltrials.gov (NCT06412666).
Travel Expenses
Participants who qualify to take part in the study and up to one caregiver may receive compensation for study-related travel expenses.